Treatment of aortic disease in patients with Marfan syndrome

Circulation. 2005 Mar 22;111(11):e150-7. doi: 10.1161/01.CIR.0000155243.70456.F4.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Aortic Aneurysm / drug therapy
  • Aortic Aneurysm / epidemiology
  • Aortic Aneurysm / etiology
  • Aortic Aneurysm / surgery*
  • Aortic Dissection / epidemiology
  • Aortic Dissection / etiology
  • Aortic Dissection / surgery
  • Aortic Rupture / etiology
  • Aortic Rupture / prevention & control
  • Aortic Valve / surgery
  • Aortic Valve Insufficiency / etiology
  • Case Management
  • Child
  • Female
  • Fibrillins
  • Humans
  • Male
  • Marfan Syndrome / complications*
  • Marfan Syndrome / diagnosis
  • Marfan Syndrome / genetics
  • Microfilament Proteins / deficiency
  • Microfilament Proteins / genetics
  • Middle Aged
  • Mitral Valve Prolapse / etiology
  • Mitral Valve Prolapse / surgery
  • Mutation
  • Pregnancy
  • Pregnancy Complications, Cardiovascular
  • Sinus of Valsalva / pathology
  • Survival Rate

Substances

  • Adrenergic beta-Antagonists
  • Fibrillins
  • Microfilament Proteins